Open Access Repository

Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia


Downloads per month over past year

Larance, B, Degenhardt, L, Grebely, J, Nielsen, S, Bruno, R ORCID: 0000-0001-6673-833X, Dietze, P, Lancaster, K, Larney, S, Santo, T, Shanahan, M, Memedovic, S, Ali, R and Farrell, M 2019 , 'Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia' , Addiction , pp. 1-11 , doi: 10.1111/add.14941.

PDF (Published version)
138023 - percep...pdf | Download (655kB)

| Preview


Aims: To examine perceptions of extended-release (XR) buprenorphine injections among people who regularly use opioids in Australia. Design: Cross-sectional survey prior to implementation. XR-buprenorphine was registered in Australiain November 2018. Setting Sydney, Melbourne and Hobart. Participants: A total of 402 people who regularly useopioids interviewed December 2017 to March 2018. Measurements: Primary outcome concerned the proportion of participants who believed XR-buprenorphine would be a good treatment option for them, preferred weekly versus monthlyinjections and perceived advantages/disadvantages of XR-buprenorphine. Independent variables concerned the demographic characteristics and features of current opioid agonist treatment (OAT; medication-type, dose, prescriber/dosingsetting, unsupervised doses, out-of-pocket expenses and travel distance). Findings: Sixty-eight per cent [95% confidenceinterval (CI) = 63–73%] believed XR-buprenorphine was a good treatment option for them. They were more likely to report being younger [26–35 versus > 55 years; odds ratio (OR) = 3.16, 95% CI = 1.12–8.89; P = 0.029], being female(OR = 1.67, 95% CI = 1.04–2.69; P = 0.034), P =0.016) and past-month heroin (OR = 1.81, 95% CI = 1.15–2.85; P = 0.006) and methamphetamine use (OR = 1.90,95% CI = 1.20–3.01; P = 0.006). Fifty-four per cent reported no preference for weekly versus monthly injections, 7% preferred weekly and 39% preferred monthly. Among OAT recipients (n = 255), believing XR-buprenorphine was a goodtreatment option was associated with shorter treatment episodes (1–2 versus ≥ 2 years; OR = 3.93, 95% CI = 1.26–12.22; P = 0.018), fewer unsupervised doses (≤ 8 doses past-month versus no take-aways; OR = 0.50; 95% CI = 0.27–0.93; P = 0.028) and longer travel distance (≥ 5 versus P = 0.009). Sixtynine per cent reported ‘no problems or concerns’ with potential differences in availability, flexibility and location of XRbuprenorphine. Conclusions: Among regular opioid users in Australia, perceptions of extended-release buprenorphineas a good treatment option are associated with being female, recent illicit drug use and factors relating to the (in)convenience of current opioid agonist treatment.

Item Type: Article
Authors/Creators:Larance, B and Degenhardt, L and Grebely, J and Nielsen, S and Bruno, R and Dietze, P and Lancaster, K and Larney, S and Santo, T and Shanahan, M and Memedovic, S and Ali, R and Farrell, M
Keywords: buprenorphine depot, buprenorphine injection, depot preparations, medication-assisted treatment, patient preferences, opioiduse disorder
Journal or Publication Title: Addiction
Publisher: Wiley-Blackwell
ISSN: 0965-2140
DOI / ID Number: 10.1111/add.14941
Copyright Information:

© 2019 The Authors. Addiction published by John Wiley & Sons Ltd on behalf of Society for the Study of Addiction. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Related URLs:
Item Statistics: View statistics for this item

Actions (login required)

Item Control Page Item Control Page